blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1595543

EP1595543 - Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.10.2015
Database last updated on 20.03.2026
Most recent event   Tooltip01.09.2017Lapse of the patent in a contracting state
New state(s): CY		published on 04.10.2017  [2017/40]
Applicant(s)For all designated states
Ed. Geistlich Söhne AG für Chemische Industrie
Bahnhofstrasse 40
6110 Wolhusen / CH
[2014/44]
Former [2005/46]For all designated states
ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE
Bahnhofstrasse 40
6110 Wolhusen / CH
Inventor(s)01 / Stendel, Rüdiger
Lissabonallee 30
14163 Berlin / DE
02 / Pfirrmann, Rolf Wilhelm
Schädrütistrasse 27
6006 Lucerne / CH
 [2005/46]
Representative(s)Matthews, Derek Peter, et al
Dehns
St Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
[N/P]
Former [2014/51]Matthews, Derek Peter, et al
Dehns
St Bride's House
10 Salisbury Square
London
EC4Y 8JD / GB
Former [2009/37]Matthews, Derek Peter, et al
Frank B. Dehn & Co. St Bride's House 10 Salisbury Square London
EC4Y 8JD / GB
Former [2009/04]Matthews, Derek Peter, et al
Frank B. Dehn & Co. St Bride's House 10 Salisbury Square
London EC4Y 8JD / GB
Former [2005/46]Marsden, John Christopher
Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street
London EC4V 4EL / GB
Application number, filing date05017803.705.06.2000
[2005/46]
Priority number, dateUS19990137421P04.06.1999         Original published format: US 137421 P
US19990151050P27.08.1999         Original published format: US 151050 P
US19990167681P29.11.1999         Original published format: US 167681 P
US20000174607P05.01.2000         Original published format: US 174607 P
US20000182200P14.02.2000         Original published format: US 182200 P
[2005/46]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1595543
Date:16.11.2005
Language:EN
[2005/46]
Type: A3 Search report 
No.:EP1595543
Date:02.08.2006
[2006/31]
Type: B1 Patent specification 
No.:EP1595543
Date:17.12.2014
Language:EN
[2014/51]
Search report(s)(Supplementary) European search report - dispatched on:EP04.07.2006
ClassificationIPC:A61K31/549, A61K31/513, A61P35/00
[2005/46]
CPC:
A61K38/2006 (EP,US); A61K31/00 (EP,US); A61K31/513 (EP,US);
A61K31/54 (EP,US); A61K31/549 (EP,US); A61K38/2013 (EP,US);
A61K38/21 (EP,US); A61K45/06 (EP,US); A61P25/00 (EP);
A61P27/02 (EP); A61P31/00 (EP); A61P35/00 (EP);
A61P43/00 (EP) (-)
C-Set:
A61K31/513, A61K2300/00 (US,EP);
A61K31/549, A61K2300/00 (EP,US);
A61K31/54, A61K2300/00 (US,EP);
A61K31/54, A61K31/00 (US,EP);
A61K38/2006, A61K2300/00 (EP,US);
A61K38/2013, A61K2300/00 (EP,US);
A61K38/20, A61K2300/00 (EP,US);
A61K38/21, A61K2300/00 (EP,US);
A61K38/21, A61K31/54 (US,EP)
(-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2005/46]
TitleGerman:Antineoplastische pharmazeutische Zusammensetzungen enthaltend Taurolidin oder Taurultam und 5-Fluorouracil[2005/46]
English:Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil[2005/46]
French:Composés pharmaceutiques antinéoplastiques comprenant du taurolidine ou taurultame et du 5-fluorouracile[2005/46]
Examination procedure29.01.2007Examination requested  [2007/11]
15.03.2007Despatch of a communication from the examining division (Time limit: M06)
25.09.2007Reply to a communication from the examining division
05.10.2007Despatch of a communication from the examining division (Time limit: M02)
17.12.2007Reply to a communication from the examining division
03.11.2009Despatch of communication that the application is refused, reason: substantive examination {1}
18.08.2014Despatch of a communication from the examining division (Time limit: M02)
26.08.2014Reply to a communication from the examining division
06.10.2014Communication of intention to grant the patent
07.11.2014Fee for grant paid
07.11.2014Fee for publishing/printing paid
07.11.2014Receipt of the translation of the claim(s)
Appeal following examination12.01.2010Appeal received No.  T0803/10
15.03.2010Statement of grounds filed
06.06.2014Result of appeal procedure: continuation of examination procedure
Parent application(s)   TooltipEP00304737.0  / EP1066830
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000304737) is  27.09.2004
Opposition(s)18.09.2015No opposition filed within time limit [2015/48]
Fees paidRenewal fee
17.08.2005Renewal fee patent year 03
17.08.2005Renewal fee patent year 04
17.08.2005Renewal fee patent year 05
17.08.2005Renewal fee patent year 06
26.06.2006Renewal fee patent year 07
14.06.2007Renewal fee patent year 08
26.03.2008Renewal fee patent year 09
24.06.2009Renewal fee patent year 10
25.06.2010Renewal fee patent year 11
28.06.2011Renewal fee patent year 12
31.03.2012Renewal fee patent year 13
26.06.2013Renewal fee patent year 14
25.06.2014Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBE17.12.2014
CY17.12.2014
DK17.12.2014
FI17.12.2014
MC17.12.2014
GR18.03.2015
PT17.04.2015
IE05.06.2015
LU05.06.2015
CH30.06.2015
LI30.06.2015
[2017/40]
Former [2016/24]BE17.12.2014
DK17.12.2014
FI17.12.2014
MC17.12.2014
GR18.03.2015
PT17.04.2015
IE05.06.2015
LU05.06.2015
CH30.06.2015
LI30.06.2015
Former [2016/22]DK17.12.2014
FI17.12.2014
MC17.12.2014
GR18.03.2015
PT17.04.2015
IE05.06.2015
LU05.06.2015
CH30.06.2015
LI30.06.2015
Former [2016/20]DK17.12.2014
FI17.12.2014
MC17.12.2014
GR18.03.2015
PT17.04.2015
IE05.06.2015
LU05.06.2015
Former [2016/11]DK17.12.2014
FI17.12.2014
MC17.12.2014
GR18.03.2015
PT17.04.2015
LU05.06.2015
Former [2016/09]DK17.12.2014
FI17.12.2014
MC17.12.2014
GR18.03.2015
PT17.04.2015
Former [2015/50]DK17.12.2014
FI17.12.2014
GR18.03.2015
PT17.04.2015
Former [2015/35]FI17.12.2014
GR18.03.2015
PT17.04.2015
Former [2015/24]FI17.12.2014
GR18.03.2015
Former [2015/23]FI17.12.2014
Documents cited:Search[A] WO9200743  (GEISTLICH SOEHNE AG et al.) [A] 1-6 * abstract *
 [A]   DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 1987 (1987-01-01), BOGDAHN U ET AL: "Therapy of malignant brain tumors: comparison of the in vitro activities of vidarabin-monophosphate, BCNU and 5-fluorouracil.", XP002386256, Database accession no. NLM3577665 [A] 1-6 * abstract *
 [A]   ACTA NEUROLOGICA SCANDINAVICA. JAN 1987, vol. 75, no. 1, January 1987 (1987-01-01), pages 28 - 36, ISSN: 0001-6314
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.